The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 26, 2024

Filed:

Dec. 06, 2021
Applicant:

Medabome, Inc., Fremont, CA (US);

Inventors:

Mason Lu, Fremont, CA (US);

Qinhong Ma, Fremont, CA (US);

Assignee:

MEDABOME, INC., Fremont, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 35/17 (2015.01);
U.S. Cl.
CPC ...
C07K 16/2896 (2013.01); A61K 35/17 (2013.01); C07K 16/2863 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01);
Abstract

The present invention provides a therapeutic agent for the treatment, prevention and diagnosis of cancers associated with cells that overexpressing transferrin receptor 1 (TfR1) and its variants on the cell surface, including but not limited to AML, ALL, lymphoma, multiple myeloma, breast cancer, gastric cancer, glioblastoma, prostate cancer, urothelial bladder cancer, pancreatic cancer, esophageal cancer, colorectal cancer, ovarian cancer, liver cancer. The agent is based on the amino acid sequences of the novel light chain and heavy chain variable regions of an anti-TfR1 monoclonal antibody (mAb), MAb11-22.1, which, is highly specific for tumor cells and in an ADC form, can functionally inhibit the proliferation of several human cancer cell lines and the growth of AML cell line-derived xenograft tumors in mouse models.


Find Patent Forward Citations

Loading…